Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Pemetrexed in Leptomeningeal Metastasis
NCT06762080Phase 2Active, not recruiting
- Sponsor
- Guangzhou Medical University
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in leptomeningeal metastasis (LM), sponsored by Guangzhou Medical University. Started Mar 2025; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT06762080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762080.